"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 3 | 5 |
| 1998 | 9 | 5 | 14 |
| 1999 | 1 | 0 | 1 |
| 2000 | 5 | 2 | 7 |
| 2001 | 6 | 2 | 8 |
| 2002 | 11 | 5 | 16 |
| 2003 | 2 | 8 | 10 |
| 2004 | 8 | 8 | 16 |
| 2005 | 10 | 6 | 16 |
| 2006 | 5 | 12 | 17 |
| 2007 | 8 | 12 | 20 |
| 2008 | 9 | 21 | 30 |
| 2009 | 7 | 9 | 16 |
| 2010 | 11 | 8 | 19 |
| 2011 | 3 | 3 | 6 |
| 2012 | 9 | 7 | 16 |
| 2013 | 10 | 9 | 19 |
| 2014 | 15 | 8 | 23 |
| 2015 | 13 | 15 | 28 |
| 2016 | 15 | 8 | 23 |
| 2017 | 19 | 11 | 30 |
| 2018 | 8 | 12 | 20 |
| 2019 | 5 | 10 | 15 |
| 2020 | 13 | 10 | 23 |
| 2021 | 11 | 11 | 22 |
| 2022 | 2 | 10 | 12 |
| 2023 | 1 | 9 | 10 |
| 2024 | 4 | 7 | 11 |
| 2025 | 6 | 6 | 12 |
| 2026 | 6 | 5 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation. ACS Nano. 2026 Sep 08; 20(35):24334-24352.
-
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort. Am J Hematol. 2026 Nov; 101(11):2827-2835.
-
Angiotensin Type 1 Receptor Antibody Positivity in a Pediatric Liver Transplant Patient With Antibody-Mediated Rejection: A Case Report. Pediatr Transplant. 2026 Aug; 30(8):e70413.
-
Topical cyclosporine A therapy for dry eye disease. Cochrane Database Syst Rev. 2026 07 17; 7:CD010051.
-
Vaccination for Patients With Immunosuppression and Altered Immunity: A Workgroup Report from the AAAAI Adverse Reactions to Drugs, Biologics, and Vaccines Committee and the Autoimmunity and Altered Immune Response Committee. J Allergy Clin Immunol Pract. 2026 07; 14(7):1549-1561.
-
AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Posttransplant management. Liver Transpl. 2026 Nov 01; 32(11):1554-1595.
-
A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients. Am J Transplant. 2026 Sep; 26(9):2099-2110.
-
Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review. Expert Opin Drug Saf. 2026 Oct; 25(10):1835-1848.
-
Kidney Transplant Outcomes in Coatomer Protein Complex Subunit Alpha (COPA) Syndrome: Report of Five Patients. Am J Kidney Dis. 2026 Jul; 88(1):170-176.
-
Evaluation of hematocrit-adjusted conversion strategies for mycophenolic acid and tacrolimus monitoring using volumetric absorptive microsampling in lung and renal transplant recipients. J Pharm Pharm Sci. 2026; 29:16123.